Core Insights - Rapport Therapeutics, Inc. is hosting its inaugural Investor and Analyst Day on June 2, 2025, in New York City, which will also be webcast live [1][3] Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [4] - The company utilizes a unique RAP technology platform based on discoveries related to receptor associated proteins (RAPs) in the brain, aiming to create precision small molecule candidates [4] - The lead investigational drug, RAP-219, targets specific regions of the brain and is being developed for refractory focal epilepsy, bipolar mania, and diabetic peripheral neuropathic pain [4] Event Details - The Investor and Analyst Day will feature a review of the company's clinical programs, particularly the RAP-219 Phase 2a trial in refractory focal epilepsy [2] - A fireside chat with Dr. Jacqueline A. French, a prominent figure in epilepsy research, will be part of the event [2] - The event is scheduled for June 2, 2025, from 3:00 to 5:00 p.m. Eastern Time at Nasdaq MarketSite, New York City [3]
Rapport Therapeutics to Host 2025 Investor and Analyst Day